Senseonics raises annual sales outlook to $68–70m on US uptake of implantable CGM

Senseonics Holdings said sales reached $19.6m in the three months to September, which it described as growth of roughly 140%. The company credited demand in the US for Eversense 365, an implantable continuous glucose monitor (CGM) that is worn for a year at a time. The comparison period for the growth figure was not given in the material available.

On the back of that performance, management now expects 2026 revenue of $68–70m and a gross margin above 60%. The earlier guidance ranges were not included in the information available, so the size of the increase cannot be stated. The third-quarter gross margin was about 62%, which sits within the new full-year margin guidance.

Profitability remains distant. The company reported a net loss of $32.7m for the quarter, so the faster sales and healthier margin have yet to close the gap between revenue and operating costs. The material available does not break down that loss or say anything about cash resources.

Senseonics also pointed to two product developments. It intends to connect Eversense 365 with the iLet automated insulin delivery system from Beta Bionics in the fourth quarter of 2026. It has also begun testing Freedom, its next-generation CGM, in people for the first time. No regulatory timetable for Freedom has been disclosed.